Advertisement


Nicholas C. Turner, MD, PhD, on Treating Emergent ESR1 Mutations in Advanced Breast Cancer

2025 ASCO Annual Meeting

Advertisement

Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, presents findings from the phase III, double-blind ctDNA-guided SERENA-6 trial, which evaluated the combination of camizestrant plus a CDK4/6 inhibitor to treat emergent ESR1 mutations during first-line endocrine therapy for patients with HR-positive, HER2-negative advanced breast cancer (LBA4). 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Here at ASCO, we're presenting the results of the SERENA-6 study in the plenary session. SERENA-6 is a study for patients who've got metastatic advanced breast cancer that's hormone receptor-positive, HER2-negative on their first-line aromatase inhibitor and CDK4/6. We know in this setting, up to 40% of patients can acquire ESR1 mutations in their cancer as the key mechanism of resistance. We also know we can use liquid biopsies to detect these ESR1 mutations emerging long before disease progression. In SERENA-6, we recruited over 3,000 patients into surveillance with sequential liquid biopsies every two to three months to detect those ESR1 mutations at the earliest stages. 315 patients were then randomized to the standard of care, which was to continue AI and CDK4/6 inhibitor or to switch from AI to camizestrant and CDK4/6. Camizestrant is a next-generation oral SERD. It’s been designed specifically to target these estrogen receptor mutations as well as the wild-type ER. It completely inhibits ER signaling as well as degrades the mutant receptor. And what we then showed is that by switching to camizestrant, we over doubled progression-free survival in the study. And very importantly, 24 months after randomization, only 5% of patients in the control arm were without progression, whereas those who switched over to camizestrant when we detect an ESR1 mutation, 30% of them were without progression. And we're starting to see a real tail on the curve emerge. Also, we looked at quality of life and time to deterioration of quality of life in the study, and we saw a very substantial prolongation in the time to deterioration in quality of life—almost out to two years in the camizestrant group by switching ahead of disease progression. So in SERENA-6, we're trying to bring forward a new way of treating people with advanced hormone receptor-positive breast cancer to prolong first-line therapy. Currently, we don't know the optimal time to change therapy. We have to wait until disease progression. The tumor starts to grow on the scan again. But this can cause symptoms and it's often a real psychological blow for patients. And so what we are doing here is identifying much earlier exactly when the tumor is beginning to develop resistance to therapy and then switching to an effective therapy that targets those ESR1 mutations and keeps the patient well on first-line therapy for longer.

Related Videos

Breast Cancer

Hope S. Rugo, MD, FASCO, and Rebecca Alexandra Dent, MD, FASCO, on Breast Cancer Data Highlights: Sequencing of Endocrine Therapy

Hope S. Rugo, MD, FASCO, of City of Hope, and Rebecca Alexandra Dent, MD, FASCO, of National Cancer Centre Singapore, review the results of a biomarker analysis of the DESTINY-Breast06 trial, which evaluated trastuzumab deruxtecan after endocrine therapy in patients with metastatic breast cancer (Abstract 1013). They also discuss findings from the SERENA-6 and EMBER-3 trials, also presented at ASCO 2025, and what all this new data means for the sequencing of endocrine therapy in patients with breast cancer. 

Lung Cancer

Luis G. Paz-Ares, MD, PhD, on Extensive-Stage SCLC: Comparison of First-Line Regimens

Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, discusses data from the TIGOS trial, a phase III study comparing the first-line use of atigotatug (an antifucosyl-GM1 monoclonal antibody) plus nivolumab fixed-dose combination with chemotherapy vs atezolizumab with chemotherapy in patients with  extensive-stage small cell lung cancer (SCLC) (Abstract TPS8127).

 

Hematologic Malignancies

Andrew Kuykendall, MD, on Hepcidin Mimetic for Polycythemia Vera

Andrew Kuykendall, MD, of Moffitt Cancer Center, discusses findings from the phase III VERIFY trial, which compared the efficacy of rusfertide vs placebo in patients with polycythemia vera who continue their current standard of care therapy (Abstract LBA3). 

CNS Cancers

Manmeet Singh Ahluwalia, MD, MBA, FASCO, on Liquid Biopsy in Glioblastoma

Manmeet Singh Ahluwalia, MD, MBA, FASCO, of Miami Cancer Institute, Baptist Health South Florida, discusses the ongoing LIBERATE trial, which is evaluating safety and technical efficacy of transcranial MR-guided microbubble-enhanced transcranial focused ultrasound for increasing blood circulating tumor and cell-free DNA levels in adults with glioblastoma (Abstract TPS2094). 

Prostate Cancer

Eric Huttenlocher Bent, MD, PhD, on Oligometastatic Prostate Cancer: Intensified Hormonal Blockade

Eric Huttenlocher Bent, MD, PhD, of Memorial Sloan Kettering Cancer Center, reviews results from the phase II Metacure trial (cohorts B2 and the B2 expansion), which looked at the efficacy of stereotactic body radiotherapy for PSMA-PETdetected oligometastatic prostate adenocarcinoma (Abstract 5014). 

Advertisement

Advertisement




Advertisement